Retatrutide and its effects on bowel habits is a question many people are asking as interest in this investigational triple receptor agonist grows. Retatrutide simultaneously targets GLP-1, GIP, and glucagon receptors, making it distinct from approved agents such as semaglutide (Wegovy) and tirzepatide (Mounjaro). Because GLP-1 receptor activation is known to alter gut motility and gastric emptying, changes in bowel habits — including both diarrhoea and constipation — have been reported in early clinical trials. This article explains the digestive effects observed so far, why they occur, how to manage them, and what current UK regulatory guidance says about this unapproved medicine.

How Retatrutide Affects the Digestive System

Retatrutide activates GLP-1 receptors throughout the gut, slowing gastric emptying and altering bowel motility; its additional glucagon receptor activity may further complicate GI effects, though this is not yet fully established.

Retatrutide is an investigational triple receptor agonist currently under clinical development. It simultaneously targets three hormone receptors: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. This triple-action mechanism distinguishes it from existing approved agents such as semaglutide (a GLP-1 receptor agonist, approved in the UK as Wegovy and Ozempic) and tirzepatide (a dual GIP/GLP-1 receptor agonist, approved as Mounjaro), and is being studied primarily for obesity and type 2 diabetes management.

Because retatrutide activates GLP-1 receptors, it directly influences gastrointestinal (GI) function. GLP-1 receptors are widely distributed throughout the gut, and their activation slows gastric emptying — the rate at which food moves from the stomach into the small intestine. This slowing effect is central to the drug's appetite-suppressing properties but also has downstream consequences for bowel motility and transit time. These GI effects are consistent with the class effects documented in the UK Summaries of Product Characteristics (SmPCs) for approved GLP-1-based medicines such as Wegovy and Mounjaro.

The glucagon receptor component adds further complexity. Glucagon is known to influence gut motility, and it is plausible that stimulating these receptors may contribute to altered bowel function; however, the precise effects of chronic glucagon receptor agonism on human GI physiology are not yet fully established. As a result, the digestive effects of retatrutide are likely to be multifactorial, involving changes in gastric emptying and intestinal transit, though the full picture will only emerge from ongoing and future trials. Mechanistic statements in this area should be understood as extrapolations from class pharmacology and early clinical data rather than established fact.

Bowel Changes Reported in Clinical Trials

Phase 2 trial data show nausea, vomiting, diarrhoea, and constipation are the most common GI side effects of retatrutide, with incidence increasing at higher doses.

Retatrutide is not yet approved by the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA), and is currently being evaluated in clinical trials. Data published to date — including results from a Phase 2 trial published in The New England Journal of Medicine in 2023 (Jastreboff et al., NEJM 2023) — provide early insights into its gastrointestinal tolerability profile. Readers should note that this evidence reflects a single Phase 2 study of limited duration; long-term GI data are not yet available. Current trial phase and status can be verified via ClinicalTrials.gov or the EU Clinical Trials Register.

In that Phase 2 trial, gastrointestinal adverse events were among the most commonly reported side effects, particularly at higher doses. These included:

• Nausea (the most frequently reported GI symptom)

• Vomiting

• Diarrhoea

• Constipation

Decreased appetite was also commonly reported, though this is better understood as a pharmacodynamic effect of the drug rather than a GI adverse event in the conventional sense.

Interestingly, both diarrhoea and constipation were reported, reflecting the variable nature of GI responses seen across this class of drug. Some participants experienced looser or more frequent stools, whilst others reported the opposite. The incidence of these effects appeared to be dose-dependent, with higher doses associated with greater GI burden. Most events were described as mild to moderate in severity and tended to occur early in treatment, often improving as the body adjusted to the medication.

These findings are preliminary. Larger trials are ongoing, and a more comprehensive safety profile — including the full spectrum of bowel-related effects — will emerge as more data become available. Patients and clinicians should interpret current evidence with appropriate caution given the drug's investigational status.

Why GLP-1 Receptor Agonists Can Alter Bowel Habits

GLP-1 receptor activation delays gastric emptying and influences the enteric nervous system, causing variable bowel changes — constipation, diarrhoea, or altered stool consistency — depending on the individual and dose.

To understand why retatrutide may affect bowel habits, it is helpful to consider the broader pharmacology of GLP-1 receptor agonists as a class. GLP-1 is an incretin hormone naturally secreted by L-cells in the small intestine in response to food intake. When GLP-1 receptors in the gut are activated — whether by endogenous hormone or by a receptor agonist drug — several physiological changes occur.

The most clinically relevant of these is delayed gastric emptying. When food remains in the stomach longer, the entire digestive process slows, which can lead to a sensation of fullness, reduced appetite, and altered stool consistency or frequency. In some individuals, this slowing effect extends to the large bowel, contributing to constipation. In others — particularly at higher doses or during dose escalation — the net effect may be altered intestinal motility and transit patterns that result in looser stools or diarrhoea. These variable responses are consistent with GI adverse reactions documented in the SmPCs for approved GLP-1-based medicines (see, for example, the EMC SmPCs for Wegovy and Mounjaro).

Additionally, GLP-1 receptors are present in the enteric nervous system — the network of nerves governing gut function — and activation here may independently influence peristalsis (the wave-like muscle contractions that move contents through the bowel). The glucagon receptor component of retatrutide may further modulate these effects, as glucagon is known to influence gut motility; however, the precise contribution of glucagon receptor agonism to bowel symptoms during chronic triple-agonist therapy remains uncertain and should be interpreted cautiously. The interplay between these three receptor pathways makes predicting individual bowel responses challenging, and highlights why clinical trial participants have reported a range of GI symptoms rather than a single consistent pattern.

Managing Gastrointestinal Side Effects Safely

Eating smaller meals, staying hydrated, avoiding high-fat foods, and increasing dietary fibre are first-line strategies for managing GI side effects; troublesome symptoms should be discussed with a clinician before adjusting treatment.

For individuals participating in retatrutide clinical trials, or for those following developments in this area ahead of potential future approval, understanding how to manage GI side effects is important. The strategies used for managing GI symptoms with existing GLP-1 receptor agonists — such as semaglutide and tirzepatide — are likely to be broadly applicable, though retatrutide-specific guidance will develop as more clinical experience accumulates.

Practical measures that may help reduce GI discomfort include:

• Eating smaller, more frequent meals rather than large portions, to reduce the burden on a stomach that is already emptying more slowly

• Avoiding high-fat or heavily processed foods, which can exacerbate nausea and slow digestion further

• Staying well hydrated, particularly if diarrhoea is present, to prevent dehydration

• Eating slowly and chewing food thoroughly to ease the digestive process

• Avoiding lying down immediately after eating, which can worsen nausea

For constipation specifically, increasing dietary fibre intake (fruits, vegetables, and wholegrains) and maintaining adequate fluid intake are first-line approaches consistent with NHS dietary guidance. Over-the-counter laxatives, anti-diarrhoeals, or antiemetics may be considered if dietary measures are insufficient, but should be discussed with a pharmacist or healthcare professional before use.

Dose escalation schedules in GLP-1-based therapies are typically gradual precisely to allow the body to adapt and to minimise GI side effects — a principle acknowledged in NICE guidance on approved agents (see NICE TA875). Participants in retatrutide trials will be guided by their trial team on dose adjustments. Anyone using an approved GLP-1 agent who experiences troublesome GI symptoms should speak to their prescribing clinician before making any changes to their regimen. If you need urgent advice when your GP surgery is closed, contact NHS 111 (online at 111.nhs.uk or by telephone).

When to Seek Medical Advice About Digestive Symptoms

Seek urgent medical advice for persistent diarrhoea, severe abdominal pain, blood in stools, or signs of dehydration; call 999 or go to A&E for sudden severe abdominal pain or signs of bowel obstruction.

Whilst mild and transient GI symptoms are common with GLP-1 receptor agonists and are generally not a cause for alarm, certain symptoms warrant prompt medical attention. Knowing when to contact a GP, call NHS 111, or seek emergency care is an important aspect of patient safety.

Contact your GP or healthcare team if you experience:

• Persistent diarrhoea lasting more than 48–72 hours, or diarrhoea accompanied by signs of dehydration (dizziness, dark urine, dry mouth)

• Severe or worsening abdominal pain, particularly if it radiates to the back — this may rarely indicate pancreatitis, a recognised risk associated with GLP-1 receptor agonists

• Pain in the upper right abdomen, fever, or yellowing of the skin or eyes (jaundice), which may suggest gallbladder disease — a known class-related concern with GLP-1-based therapies

• Blood in your stools or black, tarry stools, which require urgent investigation

• Persistent vomiting that prevents you from keeping fluids down

• Unexplained significant weight loss beyond what is expected from treatment

• Symptoms that are severely impacting your daily life or quality of life

Seek emergency care (call 999 or go to A&E) if you develop:

• Sudden, severe abdominal pain

• Severe abdominal distension, inability to pass wind or stools, or signs of possible bowel obstruction

• Signs of serious dehydration or collapse

• Chest pain alongside GI symptoms

If you are unsure whether your symptoms require emergency attention, contact NHS 111 for urgent advice.

For participants in clinical trials, all adverse events — including GI symptoms — should be reported to the trial team as per the study protocol, regardless of perceived severity. This reporting is essential for building the safety evidence base for retatrutide. For patients on approved GLP-1 therapies, suspected adverse effects can also be reported via the MHRA's Yellow Card scheme at yellowcard.mhra.gov.uk.

What Current Evidence and MHRA Guidance Says

Retatrutide is not approved by the MHRA or EMA and has no UK prescribing guidance; available evidence is limited to a single Phase 2 trial, and access should only be sought through registered clinical trials.

It is important to be clear about retatrutide's current regulatory status in the United Kingdom. As of the time of writing, retatrutide has not been approved by the MHRA or the EMA for any indication. It remains an investigational medicinal product, and therefore there is no official MHRA prescribing information, Summary of Product Characteristics (SmPC), or NICE guidance specific to retatrutide. Any use outside of authorised clinical trials would be unlicensed and is not recommended. Current trial phase and registration details can be verified via ClinicalTrials.gov or the EU Clinical Trials Register.

The available evidence on retatrutide's GI effects — including its potential to alter bowel habits — comes primarily from a Phase 2 clinical trial (Jastreboff et al., NEJM 2023). Whilst this data is promising in terms of efficacy for weight reduction and glycaemic control, the full safety and tolerability profile, including long-term GI effects, has not yet been established. Regulatory agencies including the MHRA require robust data from adequately powered trials before granting marketing authorisation.

For context, NICE guidance on existing approved GLP-1 receptor agonists — for example, NICE TA875 (Semaglutide for managing overweight and obesity, 2023) — acknowledges GI side effects as a recognised class effect and supports gradual dose escalation to improve tolerability. The UK SmPCs for Wegovy (semaglutide 2.4 mg) and Mounjaro (tirzepatide), available via the Electronic Medicines Compendium (EMC), provide detailed information on GI adverse reactions and class-related warnings such as pancreatitis and gallbladder disease. It is reasonable to anticipate that similar principles may apply to retatrutide if and when it receives approval, though this remains speculative at this stage.

Patients interested in retatrutide should be aware that there is currently no MHRA-approved treatment pathway for this drug, and should be cautious of any sources claiming otherwise. Those wishing to access it should do so only through legitimate, registered clinical trials. For up-to-date information on approved weight management treatments, the NHS website and NICE guidelines remain the most reliable UK sources.

Frequently Asked Questions